BerGenBio Presents Key Results from PhII Programme with Selective AXL Inhibitor Bemcentinib at DNB’s 9th Annual Nordic Healthcare Conference
· Bemcentinib proof of concept clinical data as monotherapy and in combination confirms focus on lung cancer & leukaemia · AXL biomarker correlation supports bemcentinib’s proposed MoA, potential for Companion Diagnostic · Significant milestones expected over next 12 monthsBergen, Norway, 12 Dec 2018 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company focused on developing a pipeline of first-in-class AXL kinase inhibitors to treat multiple cancer indications, announces that the Company will be presenting key results from its Phase II clinical programme with